Pathstone Holdings
CORT icon

Pathstone Holdings’s Corcept Therapeutics CORT Stock Holding History

Pathstone Holdings’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$987K Sell
11,355
-696
-6% -$42K ﹤0.01% 1514
2026
Q1 		$486K Sell
12,051
-4,737
-28% -$177K ﹤0.01% 1765
2025
Q4 		$584K Sell
16,788
-1,225
-7% -$96.2K ﹤0.01% 1683
2025
Q3 		$1.5M Buy
18,013
+144
+0.8% +$10.4K 0.01% 1184
2025
Q2 		$1.31M Sell
17,869
-1,296
-7% -$94K 0.01% 1248
2025
Q1 		$2.19M Buy
19,165
+5,951
+45% +$362K 0.01% 929
2024
Q4 		$666K Sell
13,214
-220
-2% -$11.5K ﹤0.01% 1596
2024
Q3 		$622K Buy
13,434
+609
+5% +$21.6K ﹤0.01% 1627
2024
Q2 		$417K Buy
12,825
+3,331
+35% +$91.2K ﹤0.01% 1790
2024
Q1 		$239K Sell
9,494
-7,974
-46% -$188K ﹤0.01% 2054
2023
Q4 		$567K Buy
+17,468
New +$480K ﹤0.01% 1425

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's CORT Position: Q2 2026 in Review

Pathstone Holdings reduced its Corcept Therapeutics (CORT) stake by 5.8% in Q2 2026, selling an estimated $42K and leaving 11,355 shares worth $987K. The position accounts for ﹤0.01% of the portfolio, ranked #1514.

Pathstone Holdings first reported a position in CORT in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.19M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Pathstone Holdings held 11,355 shares of Corcept Therapeutics worth $987K as of Q2 2026.
  • Pathstone Holdings sold 696 Corcept Therapeutics shares in Q2 2026, an estimated $42K.
  • Corcept Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1514 holding.
  • Pathstone Holdings first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Corcept Therapeutics position peaked at $2.19M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.